nach oben

Erschienen in:

08.12.2021 | Polymyositis | Zertifizierte Fortbildung

Erworbene Muskelerkrankungen

Vom Steroid zu Biologika bei Myositis: Therapiestrategien und Verlaufsskalen

verfasst von: Dr. med. Stefanie Meyer, Dr. med. Sabrina Zechel, Dr. med. Jana Zschüntzsch

Erschienen in: NeuroTransmitter | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Auszug

Nicht infektiöse Myositiden sind eine heterogene Gruppe von erworbenen Muskelerkrankungen, für die sich, Dank einer zunehmend interdisziplinären Betreuung und einer nach Krankheitsstadien ausgerichteten medikamentösen Therapie, das Langzeitergebnis der Behandlungen substanziell verbessert hat. …

Lundberg IE, Tjärnlund A, Bottai M et al. EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and their Major Subgroups. Ann Rheum Dis 2017;76:1955-64

Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nature Reviews Rheumatology 2018;14:269-78

Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis 5:109-29

Dobloug C et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Annals of the Rheumatic Diseases 2015;74:1551-6

Carstens P-O, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 2014;175:349-58

Lu Z et al. Cardiac Involvement in Adult Polymyositis or Dermatomyositis: a Systematic Review. Clin Cardiol 2012;35:685-91

Cobo-Ibáñez T et al. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin Rheumatol 2019;38:803-15

Tanizawa K et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med 2017;127:57-64

Long K, Danoff SK. Interstitial Lung Disease in Polymyositis and Dermatomyositis. Clinics in Chest Medicine 2019;40:561-72

10.

András C et al. Retrospective Analysis of Cancer-Associated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort. Pathol Oncol Res 2020;26:1749-55

11.

Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006;25:234-9

12.

Lu X et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 2014; 9:e94128

13.

Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. Journal of Neurology, Neurosurgery & Psychiatry 2009;80:1186-93

14.

Day JA et al. Radiographic patterns of muscle involvement in the idiopathic inflammatory myopathies. Muscle & Nerve 2019;60:549-57

15.

Alfano LN et al. The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis. Neuromuscul Disord 2014; 24:222-6

16.

Alexanderson Het al. Muscle Strength and Muscle Endurance During the First Year of Treatment of Polymyositis and Dermatomyositis: a Prospective Study. The Journal of Rheumatology 2018;45:538-46

17.

Regardt Met al. Patients' Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure - Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. J Rheumatol 2015;42:2492-5

18.

Alexanderson H et al. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007 Jun 15;57(5):768-77

19.

Alemo Munters L et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther 2013;15:R83

20.

Arnardottir Set al. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003;35:31-5

21.

Johnson LG et al. Improvement in Aerobic Capacity After an Exercise Program in Sporadic Inclusion Body Myositis. Journal of Clinical Neuromuscular Disease 2009;10:178-84

22.

Spector SA et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997;20:1242-8

23.

Cox FM et al.Detecting dysphagia in inclusion body myositis. J Neurol 2009;256:2009-13

24.

Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics 2018;15:995-1005

25.

Schrey A, Airas L, Jokela M, Pulkkinen J (2017) Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. Journal of the Neurological Sciences 380:142-7

26.

Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012 Aug 15;2012(8):CD003643

27.

Choy EH, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005 Jul 20;(3):CD003643.

28.

Corley CC, Lessner HE, Larsen WE. Azathioprine therapy of "autoimmune" diseases. Am J Med 1966;41:404-12

29.

Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 2018;28:913-21

30.

Vermaak E et al. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin Rheumatol 2015;34:2089-95

31.

Casal-Dominguez M et al. Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. Clin Exp Rheumatol 2019;37:858-61

32.

Morganroth PA et al. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 201;62:1496-501

33.

Tsuchiya Het al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol 2014;24:694-6

34.

Mitsui T, Kuroda Y, Ueno S-I, Kaji R. The effects of FK506 on refractory inflammatory myopathies. Acta Neurol Belg 2011;111:188-94

35.

Dalakas MC. Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA 2004;291:2367

36.

Anh-Tu Hoa S, Hudson M. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. Semin Arthritis Rheum 2017;46:488-508

37.

Dalakas MC. Controlled Studies with High-Dose Intravenous Immunoglobulin in the Treatment of Dermatomyositis, Inclusion Body Myositis, and Polymyositis. Neurology 1998;51:37

38.

Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10 % in patients with dermatomyositis ("ProDERM Study"). Medicine (Baltimore) 2021 Jan 8;100(1):e23677

39.

Danieli MG et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011;10:144-9

40.

Ge Y, Peng Q, Zhang S et al. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol 2015;34:99-105

41.

Oddis CV et al. Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis: A Randomized, Placebo-phase Trial. Arthritis Rheum 2013;65:314-24

42.

Aggarwal R, Bandos A, Reed AM et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66:740-9

43.

Valiyil R et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: A case series. Arthritis Care Res (Hoboken) 2010 Sep;62(9):1328-34

44.

Albrecht K, Huscher D, Callhoff J, Richter JG, Alexander T, Henes J, Zink A. Trends in idiopathic inflammatory myopathies: cross-sectional data from the German National Database. Rheumatol Int 2020;40:1639-47

45.

de Souza FHC et al. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Adv Rheumatol 2018;58:31

46.

Tjärnlund A, Tang Q, Wick C et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis 2018;77:55-62

47.

Zong M, Dorph C, Dastmalchi M et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 2014;73:913-20

48.

Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol 2020;39:289-301

49.

Schiffenbauer A, Garg M, Castro C et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum 2018;47:858-64

50.

Narazaki M. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011;50:1344-1346

51.

Greenberg SA et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78

52.

Walsh RJ et al. Type I Interferon-Inducible Gene Expression in Blood Is Present and Reflects Disease Activity in Dermatomyositis and Polymyositis. Arthritis Rheum 2007;56:3784-92

53.

Higgs BW, Zhu W, Morehouse C et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014;73:256-62

54.

Paik JJ, Casciola-Rosen L, Shin JY et al. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis Rheumatol 2021 May;73(5):858-65

55.

Kim H et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis 2021;80:406-8

56.

Delvino P et al. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis. Rheumatology 2020;59(12):4003

57.

Walter MC et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-8

58.

Schmidt K, Schmidt J. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment. Current Opinion in Rheumatology 2017; 29:632-8

59.

Ching JK, Weihl CC. Rapamycin-induced autophagy aggravates pathology and weakness in a mouse model of VCP-associated myopathy. Autophagy 2013;9:799-800

60.

Benveniste O, Hogrel J-Y, Belin L et al. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. The Lancet Rheumatology 2021;3:e40-e48

61.

Benveniste O, Hogrel J-Y, Annoussamy M, Bachasson D, Rigolet A. Rapamycin Vs. Placebo for the Treatment of Inclusion Body Myositis: Improvement of the 6 Min Walking Distance, a Functional Scale, the FVC and Muscle Quantitative MRI. Arthritis Rheumatol 2017;69 (suppl. 10)

Titel: Erworbene Muskelerkrankungen
Vom Steroid zu Biologika bei Myositis: Therapiestrategien und Verlaufsskalen
verfasst von: Dr. med. Stefanie Meyer
Dr. med. Sabrina Zechel
Dr. med. Jana Zschüntzsch
Publikationsdatum: 08.12.2021
Verlag: Springer Medizin
Schlagwörter: Polymyositis
Polymyositis
Dermatomyositis
Azathioprin
Azathioprin
Erschienen in: NeuroTransmitter / Ausgabe 12/2021
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI: https://doi.org/10.1007/s15016-021-9307-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Vom Steroid zu Biologika bei Myositis: Therapiestrategien und Verlaufsskalen

Auszug

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

Gesundheitspolitik

Die raue Wirklichkeit.

Morbus Parkinson: Therapieoptionen bei motorischen Komplikationen

Keine Gewichtszunahme unter Johanniskrautextrakt

Ein Jahr der Höhen und Tiefen

Erfolge feiern - Zukunft gestalten

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie